Histologic transformation from NSCLC to small cell lung cancer (SCLC) is a known mechanism of resistance to third-generation EGFR-TKIs, as well as to first-line osimertinib treatment [70]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.